Table 1

Patient characteristics*

IJD (n=86)RA (n=55)AS (n=21)PsA (n=10)p Value†
Age, years60.8±8.562.2±8.658.8±8.357.2±7.60.11
Women, n (%)52 (60.5)40 (72.7)7 (33.3)5 (50.0)0.01
Disease duration (years), median (IQR)16 (8.0–25.0)16 (7.0–22.3)21 (9.5–28.0)11.5 (1.5–29.5)0.19
BMI, kg/m2 25.3±3.225.0±2.625.4±2.626.4±3.70.44
Waist circumference, cm91.4±11.190.4±8.691.6±8.696.8±11.30.24
Systolic BP, mm Hg144±19144±20145±13145±250.94
Diastolic BP, mm Hg84±983±985±987±110.53
Hypertension, n (%)51 (59.3)32 (58.2)14 (66.7)4 (40.0)0.76
Diabetes mellitus, n (%)6 (7.0)4 (7.3)2 (9.5)0 (0.0)0.60
Smoking, n (%)16 (18.6)11 (20.0)3 (14.3)2 (20.0)0.80
Family history of cardiovascular disease, n (%)12 (14.5)8 (14.5)1 (4.8)3 (30.0)0.57
Previous cardiovascular disease, n (%)9 (10.5)6 (10.9)3 (14.3)0 (0.0)0.47
Angina pectoris, n (%)18 (20.9)12 (28.6)6 (28.6)0 (0.0)0.33
Hyperlipidaemia, n (%)55 (64.0)33 (60.0)15 (71.4)7 (70.0)0.37
Lipids
 Total cholesterol, mmol/L6.4±1.16.4±1.26.3±0.96.5±1.10.88
 HDL cholesterol, mmol/L1.7±0.51.8±0.51.5±0.51.6±0.50.07
 LDL cholesterol, mmol/L4.1±1.04.0±1.14.1±0.94.2±1.00.80
 Triglycerides (mmol/L), median (IQR)1.2 (0.9–1.8)1.1 (0.9–1.6)1.6 (1.1–2.1)1.1 (0.7–2.9)0.23
Medications
 Synthetic DMARDs, n (%)48 (63.2)34 (68.0)6 (31.6)9 (90.0)0.95
 Biologic DMARDs, n (%)26 (34.2)16 (32.0)6 (31.6)5 (50.0)0.38
Inflammatory markers
 ESR (mm/hour)14.4±9.315.3±9.612.1±9.813.9±6.00.42
 CRP (mg/L), median (IQR)2.0 (1.0–4.0)3.0 (1.0–4.0)1.0 (1.0–5.0)2.5 (1.8–6.5)0.39
  • Hypertension, ≥140 mm Hg systolic, hyperlipidaemia: total cholesterol ≥6.0 mmol/L.

  • *Values expressed as mean±SD, unless indicated otherwise.

  • †Data compared by analysis of variance.

  • AS, ankylosing spondylitis; BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; IJD, inflammatory joint disease; LDL, low-density lipoprotein; PsA, psoriatic arthritis; RA, rheumatoid arthritis.